Foley Represents TCGX as Lead Investor in $127.5M Private Placement for Adverum Biotechnologies

Foley & Larder LLP represented TCG Crossover (“TCGX”) as the lead investor in the $127.5 million private placement for Adverum Biotechnologies. Additional investors included 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners, and Vivo Capital, as well two large investment management firms. Adverum Biotechnologies is a clinical-stage company […]
Foley Represents TCGX as Investor in $120M Private Placement for Silence Therapeutics

Foley & Larder LLP represented TCG Crossover (“TCGX”) as an investor in the $120 million private placement for Silence Therapeutics. Additional investors included 5AM Ventures, Frazier Life Sciences, Logos Capital, Nextech Invest (on behalf of one or more funds managed by it), Redmile Group, and Vivo Capital. Silence is a UK-headquartered biotech company pioneering the […]
Foley Represents TCGX as Lead Investor in $120M Private Financing for Mineralys Therapeutics

Foley & Larder LLP recently represented TCG Crossover (“TCGX”) as a lead investor in the $120 million private financing for Mineralys Therapeutics. TCGX was joined by RA Capital Management, as well as new investors OrbiMed and Venrock Healthcare Capital Partners and several returning investors, including Samsara BioCapital. Mineralys Therapeutics is a clinical-stage biopharmaceutical company specializing […]
How Antitrust Regulators Are Affecting M&A Transactions

In a recent webinar co-hosted by 4thly and Foley & Lardner LLP, attorneys Greg Neppl, Natasha Allen and Louis Lehot engaged in a thought-provoking discussion with 4thly’s Bret Waters. Together, they discussed the complexities of the current antitrust landscape, highlighting the challenges and uncertainties faced by companies navigating the ever-shifting merger and acquisition (M&A) landscape. […]